Capital Advantage Inc. Increases Stake in Amgen Inc. (AMGN)
Capital Advantage Inc. raised its position in Amgen Inc. (NASDAQ:AMGN) by 6.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,133 shares of the medical research company’s stock after buying an additional 122 shares during the period. Capital Advantage Inc.’s holdings in Amgen were worth $350,000 as of its most recent filing with the SEC.
Other hedge funds have also bought and sold shares of the company. Thomas J. Herzfeld Advisors Inc. purchased a new stake in shares of Amgen during the fourth quarter valued at approximately $102,000. Alpha Omega Wealth Management LLC raised its stake in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. raised its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the last quarter. Focused Wealth Management Inc raised its stake in shares of Amgen by 248.0% in the fourth quarter. Focused Wealth Management Inc now owns 870 shares of the medical research company’s stock valued at $127,000 after buying an additional 620 shares during the last quarter. Finally, Signature Estate & Investment Advisors LLC raised its stake in shares of Amgen by 13.6% in the first quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock valued at $130,000 after buying an additional 95 shares during the last quarter. 79.12% of the stock is owned by institutional investors and hedge funds.
Shares of Amgen Inc. (NASDAQ:AMGN) traded down 0.31% during midday trading on Friday, hitting $167.29. The stock had a trading volume of 1,741,936 shares. The stock has a market cap of $122.07 billion, a PE ratio of 15.24 and a beta of 1.35. The firm has a 50 day moving average price of $174.04 and a 200-day moving average price of $168.05. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $184.21.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same period last year, the company posted $2.84 EPS. The business’s revenue was up 2.1% on a year-over-year basis. Equities analysts predict that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be paid a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a yield of 2.75%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is 41.93%.
COPYRIGHT VIOLATION NOTICE: “Capital Advantage Inc. Increases Stake in Amgen Inc. (AMGN)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/19/capital-advantage-inc-buys-122-shares-of-amgen-inc-amgn-updated-updated-updated.html.
Several analysts recently commented on the company. BidaskClub lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Argus lifted their price objective on Amgen from $180.00 to $195.00 and gave the stock a “buy” rating in a report on Thursday, July 27th. UBS AG set a $180.00 price objective on Amgen and gave the stock a “hold” rating in a report on Wednesday, July 26th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $203.00 price objective (up previously from $189.00) on shares of Amgen in a report on Wednesday, July 26th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and issued a $174.00 price objective (up previously from $172.00) on shares of Amgen in a report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. Amgen currently has an average rating of “Buy” and an average price target of $186.64.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the firm’s stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total value of $451,156.80. Following the transaction, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.